Page 280 - TBE_Book_V2_2019

Chapter 12b: TBE in Estonia

Table 2: TBE reporting and vaccine prevention in Estonia

Reporting: neurologists, infectious disease specialist.

Case definition
Clinical criteria: a person with symptoms of the central nervous system
(meningitis, meningoencephalitis, encephalomyelitis, encephaloradiculitis)

Laboratory criteria for case confirmation
At least 1 of the following :
 TBE-specific IgM and IgG antibodies in blood
 TBE-specific IgM antibodies in CSF
 Seroconversion of 4-fold increase of TBE-specific antibodies in paired serum
samples
Mandatory TBE reporting  Detection of TBE viral nucleic acid in a clinical specimen
 Isolation of TBEV from clinical specimens. Probable case: detection of TBE-
specific IgM antibodies in a unique serum sample.

Epidemiological criteria
Exposure to a common source (unpasteurized dairy product).
Case classification:
 Possible case: Not applicable
 Probable case: a person meeting the clinical criteria and the laboratory
criteria for a probable case OR a person meeting the clinical criteria and
with an epidemiological link.
 Confirmed case: a person meeting the clinical and laboratory criteria for
case confirmation.

Other TBE surveillance Laboratory and epidemiological surveillance
Bi-phasic disease:
Special clinical features meningitis, meningoencephalitis, or meningoencephalomyelitis.
Risk groups: people who often spend time outdoors (in nature).
TBE vaccination by age groups in Estonia, 2016-2017
2016 2017
Age
Vaccination Revaccination Vaccination Revaccination
Available vaccines 1 - 4 3951 3412 4864 3322
15 -17 520 927 650 1129
Adults 7190 14 254 8518 13 348
Population 1 315 819 1 313 271
(Estonia)

Vaccination recommendations Vaccination recommendations 1998. No reimbursement; self-paid.
and reimbursement

Vaccine uptake by age group/
General population 2.3% (vaccinated and revaccinated).
risk group/general population

Name, address/website of TBE Institute for Health Development, Lab for Virology
NRC http://www.tai.ee/en/about-us/national-institute-for-health-development

275